Related references
Note: Only part of the references are listed.Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection
Elias B. Chahine et al.
ANNALS OF PHARMACOTHERAPY (2021)
Biopolymer-based Carriers for DNA Vaccine Design
Christoph O. Franck et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2021)
Strategies in DNA vaccine for melanoma cancer
Tayebeh Rezaei et al.
PIGMENT CELL & MELANOMA RESEARCH (2021)
Immunological approaches to HIV cure
Adam R. Ward et al.
SEMINARS IN IMMUNOLOGY (2021)
Latency Reversal 2.0: Giving the Immune System a Seat at the Table
Vidisha Singh et al.
CURRENT HIV/AIDS REPORTS (2021)
Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes
Tatiana M. Garcia-Bates et al.
EBIOMEDICINE (2021)
Nucleic acid delivery and nanoparticle design for COVID vaccines
Jason L. Andresen et al.
MRS BULLETIN (2021)
Effects of therapeutic vaccination on the control of SIV in rhesus macaques with variable responsiveness to antiretroviral drugs
Hillary Claire Tunggal et al.
PLOS ONE (2021)
PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue
Sheikh Abdul Rahman et al.
SCIENCE IMMUNOLOGY (2021)
An Update on the HIV DNA Vaccine Strategy
Joseph Hokello et al.
VACCINES (2021)
A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates
Dorien De Pooter et al.
VACCINES (2021)
T cell-based strategies for HIV-1 vaccines
Bette Korber et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2020)
Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity
Ji Wang et al.
SCIENCE (2020)
Immune checkpoint modulation enhances HIV-1 antibody induction
Todd Bradley et al.
NATURE COMMUNICATIONS (2020)
Curing HIV: Seeking to Target and Clear Persistent Infection
David M. Margolis et al.
CELL (2020)
Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
Amina Ait-Ammar et al.
FRONTIERS IN MICROBIOLOGY (2020)
Defining T Cell Tissue Residency in Humans: Implications for HIV Pathogenesis and Vaccine Design
Barbara L. Shacklett et al.
CURRENT HIV/AIDS REPORTS (2020)
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang et al.
FRONTIERS OF MEDICINE (2020)
Advances in Developing CAR T-Cell Therapy for HIV Cure
Jinxin Qi et al.
FRONTIERS IN IMMUNOLOGY (2020)
HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02)
Beatriz Mothe et al.
FRONTIERS IN IMMUNOLOGY (2020)
CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption
Justin Harper et al.
NATURE MEDICINE (2020)
Engineering CAR T Cells to Target the HIV Reservoir
Wenli Mu et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2020)
Amplifying RNA Vaccine Development
Deborah H. Fuller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo
Colby R. Maldini et al.
NATURE MEDICINE (2020)
Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Melissa Gamat-Huber et al.
CANCERS (2020)
CD8+ T cells in HIV control, cure and prevention
David R. Collins et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Application of CRISPR/Cas9-Based Gene Editing in HIV-1/AIDS Therapy
Qiaoqiao Xiao et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection
Zelalem A. Mekonnen et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2019)
Gut Microbiome Alterations During HIV/SIV Infection: Implications for HIV Cure
Katti R. Crakes et al.
FRONTIERS IN MICROBIOLOGY (2019)
Updated Studies on the Development of HIV Therapeutic Vaccine
Mona Sadat Larijani et al.
CURRENT HIV RESEARCH (2019)
A Comparison of Plasmid DNA and mRNA as Vaccine Technologies
Margaret A. Liu
VACCINES (2019)
PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy
Elena Bekerman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology
Geetha Mylvaganam et al.
FRONTIERS IN IMMUNOLOGY (2019)
Aiming for protective T-cell responses: a focus on the first generation conserved-region HIVconsv vaccines in preventive and therapeutic clinical trials
Tomas Hanke
EXPERT REVIEW OF VACCINES (2019)
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Shuang Qin et al.
MOLECULAR CANCER (2019)
Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
Tayebeh Rezaei et al.
JOURNAL OF CONTROLLED RELEASE (2019)
Functional cure of HIV: the scale of the challenge
Miles P. Davenport et al.
NATURE REVIEWS IMMUNOLOGY (2019)
Advanced physical techniques for gene delivery based on membrane perforation
Xiaofan Du et al.
DRUG DELIVERY (2018)
Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases
Max A. Cheng et al.
HUMAN GENE THERAPY (2018)
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector
Lindsey R. Baden et al.
JOURNAL OF INFECTIOUS DISEASES (2018)
S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense
Yuefeng Huang et al.
SCIENCE (2018)
Therapeutic conserved elements (CE) DNA vaccine induces strong T-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection
Paul Munson et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Langerhans Cells: Sensing the environment in Health and Disease
Julie Deckers et al.
FRONTIERS IN IMMUNOLOGY (2018)
Safety and Immunogenicity of PENNVAX-G DNA Prime Administered by Biojector 2000 or CELLECTRA Electroporation Device With Modified Vaccinia Ankara-CMDR Boost
Julie A. Ake et al.
JOURNAL OF INFECTIOUS DISEASES (2017)
Multigenic DNA vaccine induces protective cross-reactive T cell responses against heterologous influenza virus in nonhuman primates
Merika T. Koday et al.
PLOS ONE (2017)
Evaluation of the immunogenicity and impact on the latent HIV-1 reservoir of a conserved region vaccine, MVA.HIVconsv, in antiretroviral therapy-treated subjects
Gemma Hancock et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2017)
HIV Env conserved element DNA vaccine alters immunodominance in macaques
Xintao Hu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge
M. A. Kutzler et al.
MUCOSAL IMMUNOLOGY (2016)
Vaccine adjuvants as potential cancer immunotherapeutics
Burcu Temizoz et al.
INTERNATIONAL IMMUNOLOGY (2016)
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
Jeffrey M. Jacobson et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2016)
DNA Prime-Boost Vaccine Regimen To Increase Breadth, Magnitude, and Cytotoxicity of the Cellular Immune Responses to Subdominant Gag Epitopes of Simian Immunodeficiency Virus and HIV
Xintao Hu et al.
JOURNAL OF IMMUNOLOGY (2016)
Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys
Erica N. Borducchi et al.
NATURE (2016)
Latency reversal and viral clearance to cure HIV-1
David M. Margolis et al.
SCIENCE (2016)
Reversal of Latency as Part of a Cure for HIV-1
Thomas Aagaard Rasmussen et al.
TRENDS IN MICROBIOLOGY (2016)
Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination
Susan A. Holechek et al.
VACCINE (2016)
Elimination of HIV-1-infected cells by broadly neutralizing antibodies
Timothee Bruel et al.
NATURE COMMUNICATIONS (2016)
Combined eff ect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial
Steffen Leth et al.
LANCET HIV (2016)
Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
Beatriz Mothe et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques
Beatriz Mothe et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations
Kai Deng et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo
Misako Matsumoto et al.
NATURE COMMUNICATIONS (2015)
Evaluating the efficacy of therapeutic HIV vaccines through analytical treatment interruptions
Gina M. Graziani et al.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY (2015)
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Ole S. Sogaard et al.
PLOS PATHOGENS (2015)
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
Julian H. Elliott et al.
LANCET HIV (2015)
Cancer vaccine adjuvants - recent clinical progress and future perspectives
Abid H. Banday et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2015)
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
Zoe Moodie et al.
PLOS ONE (2015)
A Pilot Study Assessing the Safety and Latency-Reversing Activity of Disulfiram in HIV-1-Infected Adults on Antiretroviral Therapy
Adam M. Spivak et al.
CLINICAL INFECTIOUS DISEASES (2014)
Exploitation of Langerhans cells for in vivo DNA vaccine delivery into the lymph nodes
E. R. Toke et al.
GENE THERAPY (2014)
HIV-1 Expression Within Resting CD4+ T Cells After Multiple Doses of Vorinostat
Nancy M. Archin et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
Altered Response Hierarchy and Increased T-Cell Breadth upon HIV-1 Conserved Element DNA Vaccination in Macaques
Viraj Kulkarni et al.
PLOS ONE (2014)
Increased Generation of HIV-1 gp120-Reactive CD8+ T Cells by a DNA Vaccine Construct Encoding the Chemokine CCL3
Inger Oynebraten et al.
PLOS ONE (2014)
Intranasal Administration of a Therapeutic HIV Vaccine (Vacc-4x) Induces Dose-Dependent Systemic and Mucosal Immune Responses in a Randomized Controlled Trial
Kristin Brekke et al.
PLOS ONE (2014)
Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy
Julian H. Elliott et al.
PLOS PATHOGENS (2014)
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial
Thomas A. Rasmussen et al.
LANCET HIV (2014)
Recent Developments in Preclinical DNA Vaccination
Kenji Okuda et al.
VACCINES (2014)
Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
Jaikumar Duraiswamy et al.
CANCER RESEARCH (2013)
Safety, Tolerability, and Immunogenicity of Repeated Doses of DermaVir, a Candidate Therapeutic HIV Vaccine, in HIV-Infected Patients Receiving Combination Antiretroviral Therapy
Benigno Rodriguez et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2013)
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Masashi Shingai et al.
NATURE (2013)
Polymer multilayer tattooing for enhanced DNA vaccination
Peter C. DeMuth et al.
NATURE MATERIALS (2013)
HIV-1 p24gag Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice
Viraj Kulkarni et al.
PLOS ONE (2013)
Superior Control of HIV-1 Replication by CD8+T Cells Targeting Conserved Epitopes: Implications for HIV Vaccine Design
Pratima Kunwar et al.
PLOS ONE (2013)
Therapeutic DNA Vaccination of Vertically HIV-Infected Children: Report of the First Pediatric Randomised Trial (PEDVAC)
Paolo Palma et al.
PLOS ONE (2013)
A Dendritic Cell-Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication
Felipe Garcia et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses
Gleb Kichaev et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
N. M. Archin et al.
NATURE (2012)
Animal models for HIV/AIDS research
Theodora Hatziioannou et al.
NATURE REVIEWS MICROBIOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Therapeutic DNA Vaccine Induces Broad T Cell Responses in the Gut and Sustained Protection from Viral Rebound and AIDS in SIV-Infected Rhesus Macaques
Deborah Heydenburg Fuller et al.
PLOS ONE (2012)
Single DermaVir Immunization: Dose-Dependent Expansion of Precursor/Memory T Cells against All HIV Antigens in HIV-1 Infected Individuals
Julianna Lisziewicz et al.
PLOS ONE (2012)
HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome
Damien Z. Soghoian et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU®-Multi-HIVB, in untreated HIV-1 infected subjects
Eftyhia Vardas et al.
VACCINE (2012)
IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques
Rashmi Jalah et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
Mapping HIV-1 Vaccine Induced T-Cell Responses: Bias towards Less-Conserved Regions and Potential Impact on Vaccine Efficacy in the Step Study
Fusheng Li et al.
PLOS ONE (2011)
Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial
L. Gudmundsdotter et al.
VACCINE (2011)
Cytolytic CD4+ T cells in viral immunity
Damien Z. Soghoian et al.
EXPERT REVIEW OF VACCINES (2010)
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys
Dan H. Barouch et al.
NATURE MEDICINE (2010)
Safety and Immunogenicity of Therapeutic DNA Vaccination in Individuals Treated with Antiretroviral Therapy during Acute/Early HIV-1 Infection
Eric S. Rosenberg et al.
PLOS ONE (2010)
GM-CSF Increases Mucosal and Systemic Immunogenicity of an H1N1 Influenza DNA Vaccine Administered into the Epidermis of Non-Human Primates
Peter T. Loudon et al.
PLOS ONE (2010)
Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit
Antonio Valentin et al.
VACCINE (2010)
Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control
Adam R. Hersperger et al.
PLOS PATHOGENS (2010)
Elite control of HIV infection: implications for vaccine design
B. M. Baker et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Conserved HIV-1 Epitopes Continuously Elicit Subdominant Cytotoxic T-Lymphocyte Responses
Yi Liu et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination
Wing-Pui Kong et al.
JOURNAL OF VIROLOGY (2009)
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination
M. Manrique et al.
MUCOSAL IMMUNOLOGY (2009)
Enhancing SIV-specific immunity in vivo by PD-1 blockade
Vijayakumar Velu et al.
NATURE (2009)
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up
Olimpia Longo et al.
VACCINE (2009)
A Therapeutic SIV DNA Vaccine Elicits T-Cell Immune Responses, But No Sustained Control of Viremia in SIVmac239-Infected Rhesus Macaques
Jan zur Megede et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2008)
Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy
Cara C. Wilson et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection
Sang-Jun Ha et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy
Tae-Wook Chun et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector® vs standard needles for enfuvirtide administration
M. R. Loutfy et al.
HIV MEDICINE (2007)
Protection of mice against rotavirus challenge following intradermal DNA immunization by Biojector needle-free injection
Anthony H. -C. Choi et al.
VACCINE (2007)
CD8(+) T-cell responses to different HIV proteins have discordant associations with viral load
Photini Kiepiela et al.
NATURE MEDICINE (2007)
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
Will Fischer et al.
NATURE MEDICINE (2007)
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
Barney S. Graham et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Constantinos Petrovas et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Lydie Trautmann et al.
NATURE MEDICINE (2006)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo
Emmanuel Zorn et al.
BLOOD (2006)
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Michael R. Betts et al.
BLOOD (2006)
Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation
Gillis R. Otten et al.
VACCINE (2006)
DNA immunization in combination with effective antiretroviral drug therapy controls viral rebound and prevents simian AIDS after treatment is discontinued
DH Fuller et al.
VIROLOGY (2006)
Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector)
M Harris et al.
AIDS (2006)
Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation
AK Roos et al.
MOLECULAR THERAPY (2006)
Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients:: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine
L Dorrell et al.
AIDS (2005)
Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results in enhanced CD8 T-cell immunity and increased control of viral blips
RR MacGregor et al.
VACCINE (2005)
Virosomes for antigen and DNA delivery
T Daemen et al.
ADVANCED DRUG DELIVERY REVIEWS (2005)
Control of viral rebound through therapeutic immunization with DermaVir
J Lisziewicz et al.
AIDS (2005)
DermaVir: A novel topical vaccine for HIV/AIDS
J Lisziewicz et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2005)
Long-term persistence of vaccination and HAART to human immunodeficiency virus (HIV)
AC Boström et al.
VACCINE (2004)
Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells
JD Siliciano et al.
NATURE MEDICINE (2003)
Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection
C Chouquet et al.
AIDS (2002)
Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells
TC Becker et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2002)
HIV preferentially infects HIV-specific CD4+ T cells
DC Douek et al.
NATURE (2002)
Gene gun-mediated oral mucosal transfer of interleukin 12 cDNA coupled with an irradiated melanoma vaccine in a hamster model: Successful treatment of oral melanoma and distant skin lesion
J Wang et al.
CANCER GENE THERAPY (2001)
Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine
RB Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Induction of antigen-specific CD8+T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine
MJ Roy et al.
VACCINE (2000)
Two double-blinded, randomized, comparative trials of 4 human immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1-infected individuals across a spectrum of disease severity: AIDS clinical trials groups 209 and 214
RT Schooley et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia
TM Allen et al.
NATURE (2000)
DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells
TBH Geijtenbeek et al.
CELL (2000)
Share Paper
